Scholarlink

Background <p>Ligamentum flavum hypertrophy (LFH) is a multifactor-mediated degenerative change in the spine. Due to its complex aetiology and pathology, there is no targeted therapy for LFH in the clinic. Therefore, it is urgent to explore its potential mechanism and develop new therapeutic methods, which are conducive to the early recovery of patients. Peroxisome proliferator activated receptor γ (PPARγ), a nuclear receptor regulated by synthetic ligands and endogenous cellular lipids, is involved in a variety of biological processes. Currently, increasing evidence suggests that PPARγ may serve as a new pathway to guide the targeted treatment of LFH. Consequently, therapeutically harnessing the PPARγ signalling pathway to inhibit LFH could become a central focus of current research and clinical translation.</p> Main body <p>LFH involves multiple pathological processes, including inflammation, fibrosis, angiogenesis, extracellular matrix (ECM) deposition, apoptosis and proliferation. PPARγ plays a key regulatory role in these biological processes. We further review strategies to modulate or target the PPARγ signalling pathway, highlight the related molecular mechanisms and recent clinical advances, and discuss potential possibilities for clinical translation and future perspectives.</p> Conclusions <p>Although there is no direct evidence to support this, we found through a literature review that PPARγ may be involved in regulating various biological processes involved in the development of LFH. The PPARγ signalling pathway may be a potential therapeutic target for LFH, which provides new insights for future LFH research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PPARγ signalling pathway: molecular mechanisms and therapeutic potential in ligamentum flavum hypertrophy and lumbar spinal stenosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月15日

查看全文
  • Xue Chen,
  • Chen Zhu,
  • Shuhan Yang,
  • Yuan Zeng,
  • Bo Zhang,
  • Chen Liang,
  • Ye Tian,
  • Tuanjiang Liu,
  • Shanxi Wang

摘要

Background

Ligamentum flavum hypertrophy (LFH) is a multifactor-mediated degenerative change in the spine. Due to its complex aetiology and pathology, there is no targeted therapy for LFH in the clinic. Therefore, it is urgent to explore its potential mechanism and develop new therapeutic methods, which are conducive to the early recovery of patients. Peroxisome proliferator activated receptor γ (PPARγ), a nuclear receptor regulated by synthetic ligands and endogenous cellular lipids, is involved in a variety of biological processes. Currently, increasing evidence suggests that PPARγ may serve as a new pathway to guide the targeted treatment of LFH. Consequently, therapeutically harnessing the PPARγ signalling pathway to inhibit LFH could become a central focus of current research and clinical translation.

Main body

LFH involves multiple pathological processes, including inflammation, fibrosis, angiogenesis, extracellular matrix (ECM) deposition, apoptosis and proliferation. PPARγ plays a key regulatory role in these biological processes. We further review strategies to modulate or target the PPARγ signalling pathway, highlight the related molecular mechanisms and recent clinical advances, and discuss potential possibilities for clinical translation and future perspectives.

Conclusions

Although there is no direct evidence to support this, we found through a literature review that PPARγ may be involved in regulating various biological processes involved in the development of LFH. The PPARγ signalling pathway may be a potential therapeutic target for LFH, which provides new insights for future LFH research.